Caladrius Biosciences Inc (NASDAQ:CLBS)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - CLBS

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - CLBS

  • Market Cap$32.460m
  • SymbolNASDAQ:CLBS
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS1280582032

Company Profile

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).Caladrius Biosciences Inc is a biopharmaceutical company. The company through its subsidiary is developing cellular therapeutics to treat diseases.

Latest CLBS news

Currently there for this company. Visit our news hub for other news .